Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.
Cancer Med
; 12(24): 21680-21693, 2023 12.
Article
in En
| MEDLINE
| ID: mdl-37987139
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Med
Year:
2023
Document type:
Article
Affiliation country:
Japan
Country of publication:
United States